"A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France" [Joint Bone Spine 2008;75(same issue)] (DOI:10.1016/j.jbspin.2007.06.004);A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France

Joint Bone Spine

Volumn 75, Issue 2, 2008, Pages 201-208

  Cotté, François Emery ^a   Cortet, Bernard ^b   Lafuma, Antoine ^c   Avouac, Bernard ^d   Hasnaoui, Abdelkader El ^a   Fardellone, Patrice ^e   Pouchain, Denis ^f   Roux, Christian ^g   Gaudin, Anne Françoise ^a  

^a GLAXOSMITHKLINE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CEMKA EVAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f General Practice Department   (France)

^g Cochin Hospital ^*  (France)

Author keywords

Fracture risk; Ibandronate; Modelling study; Mortality; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; DATA BASE; FEMALE; FRANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MODEL; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; PUBLIC HEALTH PROBLEM; RISK REDUCTION; SURVIVAL; VERTEBRA FRACTURE;

EID: 40949146943     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.01.001     Document Type: Erratum

References (44)

1. Cooper C., Atkinson E.J., Jacobsen S.J., et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137 (1993) 1001-1005
2. Hasserius R., Karlsson M.K., Jonsson B., et al. Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly-a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int 76 (2005) 235-242
3. Lindsay R., Silverman S.L., Cooper C., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 285 (2001) 320-323
4. Maravic M., Le Bihan C., Landais P., et al. Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int 16 (2005) 1475-1480
5. Wehren L.E., and Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep 1 (2003) 78-85
6. Empana J.P., Dargent-Molina P., and Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 52 (2004) 685-690
7. Balasegaram S., Majeed A., and Fitz-Clarence H. Trends in hospital admissions for fractures of the hip and femur in England, 1989-1990 to 1997-1998. J Public Health Med 23 (2001) 11-17
8. Boufous S., Finch C.F., and Lord S.R. Incidence of hip fracture in New South Wales: are our efforts having an effect?. Med J Aust 180 (2004) 623-626
9. Fielden J., Purdie G., Horne G., et al. Hip fracture incidence in New Zealand, revisited. N Z Med J 114 1129 (2001) 154-156
10. Delmas P.D. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 17 (2005) 462-466
11. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
12. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
13. Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
14. Cortet B., and Benichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis?. Joint Bone Spine 73 (2006) e1-e7
15. Delmas P., Vrijens B., Roux C., et al. Osteoporosis treatment using reinforcement with bone turnover marker data reduces fracture risk: the IMPACT study. J Bone Miner Res 19 (2004) S444
16. McCombs J.S., Thiebaud P., McLaughlin-Miley C., et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
17. Lespessailles E. A forgotten challenge when treating osteoporosis: getting patients to take their meds. Joint Bone Spine 74 (2007) 7-8
18. Cramer J.A., Lynch N.O., Gaudin A.F., et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom. France. Clin Ther 28 (2006) 1686-1694
19. Silverman S.L., Chesnut C.H., Amonkar M.M., et al. Improved persistence in women treated with once-monthly ibandronate versus weekly biphosphonates: a first look. J Bone Miner Res Suppl (2006) 1 SU355
20. Emkey R., Koltun W., Beusterien K., et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (2005) 1895-1903
21. Kanis J.A., Borgstrom F., Zethraeus N., et al. Intervention thresholds for osteoporosis in the UK. Bone 36 (2005) 22-32
22. Ismail A.A., Pye S.R., Cockerill W.C., et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 13 (2002) 565-571
23. The European Prospective Osteoporosis Study Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17 (2002) 716-724
24. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
25. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
26. Heaney R.P., Zizic T.M., Fogelman I., et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13 (2002) 501-505
27. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
28. Kanis J.A., Brazier J.E., Stevenson M., et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6 (2002) 1-146
29. Roux C., Seeman E., Eastell R., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20 (2004) 433-439
30. Ross P.D., Genant H.K., Davis J.W., et al. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3 (1993) 120-126
31. Brossa Torruella A., Tobias Ferrer J., Zorrilla Ribeiro J., et al. Mortality after hip fracture: a three year follow-up study. Med Clin (Barc) 124 (2005) 53-54
32. van den Boogaard C.H., Breekveldt-Postma N.S., Borggreve S.E., et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22 (2006) 1757-1764
33. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
34. Jalava T., Sarna S., Pylkkanen L., et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18 (2003) 1254-1260
35. Kado D.M., Duong T., Stone K.L., et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int 14 (2003) 589-594
36. Kanis J.A., Oden A., Johnell O., et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15 (2004) 108-112
37. Melton III L.J. Excess mortality following vertebral fracture. J Am Geriatr Soc 48 (2000) 338-339
38. Naves M., Diaz-Lopez J.B., Gomez C., et al. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int 14 (2003) 520-524
39. Liberman U.A., Hochberg M.C., Geusens P., et al. Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int J Clin Pract 60 (2006) 1394-1400
40. Baudoin C. Present and future epidemiology of osteoporosis. Rev Prat 45 (1995) 1089-1095
41. Baudoin C., Fardellone P., Thelot B., et al. Hip fractures in France: the magnitude and perspective of the problem. Osteoporos Int 3 Suppl (1996) 1-10
42. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
43. Black D.M., Arden N.K., Palermo L., et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14 (1999) 821-828
44. Ross P.D., Davis J.W., Epstein R.S., et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114 (1991) 919-923